Aspiriant LLC’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Aspiriant LLC’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,175	Closed	-$209K	–	253
2018 Q3	$209K	Sell	2,175 -116	-5%	-$11.2K	0.02%	222
2018 Q2	$218K	Buy	+2,291	New	+$211K	0.02%	235

Other funds holding XBI

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Aspiriant LLC's XBI Position: Q4 2018 in Review

Aspiriant LLC sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 2,175 shares — an estimated $209K sold.

Aspiriant LLC first reported a position in XBI in Q2 2018 and held it in 2 quarters. The position peaked at $218K in Q2 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

Aspiriant LLC reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
Aspiriant LLC sold 2,175 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $209K.
Aspiriant LLC first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and held it in 2 quarters.
Aspiriant LLC's State Street SPDR S&P Biotech ETF position peaked at $218K in Q2 2018.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on Aspiriant LLC's 13F filing for Q4 2018, filed 4 Feb 2019.